From: Max More (max@maxmore.com)
Date: Thu Jun 28 2001 - 15:03:45 MDT
At 12:19 PM 6/28/01, you wrote:
> > -- I'm surprised not to have seen the great study by Sam Peltzman
> mentioned
> > in recent stories on the Precautionary Principle. Peltzman showed the costs
> > of delaying approval of life-saving drugs.
>
>Max, do you have a pointer to this?
I'm not sure which paper it was, and my copies of Free to Choose and Life
Extension (which refer to it) are both in storage. It may be one of these two:
Peltzman, Sam. "Regulation of pharmaceutical innovation: the 1962
amendments." Evaluative studies, 15 American Enterprise Institute for
Public Policy Research; Washington, American Enterprise Institute for
Public Policy Research, 1974.
Peltzman, Sam. "The benefits and costs of new drug regulation" Chicago
Ill.: University of Chicago, 1972.
All kinds of interesting papers here, including more recent papers by this
economist on costs of regulation:
http://www.lib.uchicago.edu/e/busecon/busfac/Peltzman.html
A recent one that would be interesting to read:
More Than Forty Prominent Economists Urge Supreme Court to Allow EPA to
Consider Costs and Consequences of Clean Air Regulations. (PDF file).
http://www.aei.brookings.org/publications/authors.asp?aID=70
Max
_______________________________________________________
Max More, Ph.D.
Futurist, Speaker, Consultant.
max@maxmore.com or more@extropy.org
http://www.maxmore.com
President, Extropy Institute. http://www.extropy.org <more@extropy.org>
________________________________________________________________
Senior Content Architect, ManyWorlds Inc.: http://www.manyworlds.com
"The Premier Business Strategy Source"
m.more@manyworlds.com
_______________________________________________________
This archive was generated by hypermail 2.1.5 : Sat Nov 02 2002 - 08:08:20 MST